Phenotypic and Genetic Correlates of Diabetes (Non-Type 1) in Young Non-Obese Asian Indians in North India and A Study to Evaluate the Efficacy of Sitagliptin (DPP-4 Inhibitor) in a Sub-group of the Study Population
|ClinicalTrials.gov Identifier: NCT00964184|
Recruitment Status : Completed
First Posted : August 24, 2009
Last Update Posted : August 6, 2015
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus, Type 2||Drug: Metformin Behavioral: Lifestyle modification||Phase 4|
A phase IV on T2DM with BMI < 25 kg/m2 and age 14-40 years.
- To investigate phenotype (body composition, anthropometry, pancreatic imaging and endocrine function, insulin resistance, autoantibodies, and other biochemical variables) and genetic (known mutations and polymorphisms) correlates in young (age 14-40 years) diabetic patients (non-type 1).
- To study anthropometric and body fat distribution including truncal fat, subcutaneous and intra-abdominal fat in non-obese young patients with diabetes (non-type 1).
- To study whether insulin secretion, insulin resistance or a combination of both is/are the predominant defect(s) in non-obese young diabetics (non-type 1).
- To study the prevalence of autoimmunity and/or specific genetic abnormalities in this subgroup of diabetics.
- To estimate approximate prevalence of diagnostic subcategories based on the sample of population, and profile of complications in each category.
- To propose rational use of specialized investigations (e.g. GAD65, HNF-1α mutations etc) while investigating a newly diagnosed young diabetic.
- To determine the rational therapeutic option and prognosis in this sub-population of diabetics based on anthropometric, biochemical, and etiological profiles.
- Sample size: 205 patients to be enrolled and 120 patients to be enrolled for sub group study
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||133 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||September 2009|
|Actual Primary Completion Date :||July 2015|
|Actual Study Completion Date :||July 2015|
1 gm metformin per day
Behavioral: Lifestyle modification
- HbA1c [ Time Frame: 18 weeks ]
- HbA1C [ Time Frame: 12 weeks ]
- Assessment of safety profile of sitagliptin [ Time Frame: 18 weeks ]
- insulin [ Time Frame: 12 weeks ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00964184
|Fortis Flt Lt Rajan Dhall Hospital|
|New Delhi, Delhi, India, 110070|
|Principal Investigator:||Anoop Misra||Diabetes Foundation, India|